These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 33829270)
21. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930 [TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Joo JW; Hong MH; Shim HS Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020 [TBL] [Abstract][Full Text] [Related]
23. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Li C; Jia R; Liu H; Zhang B; Wang C Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780 [TBL] [Abstract][Full Text] [Related]
24. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247 [TBL] [Abstract][Full Text] [Related]
25. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987 [No Abstract] [Full Text] [Related]
27. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083 [TBL] [Abstract][Full Text] [Related]
28. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations. Li XF; Shen WZ; Jin X; Ren P; Zhang J Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854 [TBL] [Abstract][Full Text] [Related]
29. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991 [TBL] [Abstract][Full Text] [Related]
30. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition. Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097 [TBL] [Abstract][Full Text] [Related]
31. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353 [TBL] [Abstract][Full Text] [Related]
32. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341 [TBL] [Abstract][Full Text] [Related]
33. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
34. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells. Liu S; Jiang Z; Xiao P; Li X; Chen Y; Tang H; Chai Y; Liu Y; Zhu Z; Xie Q; He W; Ma Y; Jin L; Feng W Cancer Sci; 2022 Jan; 113(1):79-90. PubMed ID: 34706132 [TBL] [Abstract][Full Text] [Related]
35. Mixed response to osimertinib and the beneficial effects of additional local therapy. Shinno Y; Goto Y; Sato J; Morita R; Matsumoto Y; Murakami S; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2019 Apr; 10(4):738-743. PubMed ID: 30735003 [TBL] [Abstract][Full Text] [Related]
36. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib. Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113 [TBL] [Abstract][Full Text] [Related]